Crohn's Disease
Environmental Risk and Protective Factors
Etiopathogenesis
Epidemiology
Skyrizi outperforms Stelara in endoscopic remission at week 48 in Crohn’s disease
Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.
Etiology and Pathogenesis
FDA approves biosimilar Pyzchiva for all approved Stelara indications
The FDA has approved the Stelara biosimilar Pyzchiva for psoriatic arthritis, Crohn’s disease and all other indications approved for the reference medicine, according to a press release from Sandoz.
Hormone replacement therapy improves IBD symptoms in postmenopausal women
Hormone replacement therapy was associated with improved disease symptoms, measured by the physician global assessment score, in a cohort of postmenopausal women with inflammatory bowel disease, according to data.
Higher adalimumab concentration linked to complete healing in perianal fistulizing Crohn’s
An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology.
Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD
The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.
‘Promise of lasting efficacy’: Guselkumab outperforms placebo, ustekinumab in Crohn’s
WASHINGTON — In patients with active Crohn’s disease, guselkumab was superior to both placebo and standard-of-care ustekinumab after 48 weeks of treatment, according to late-breaking data from the phase 3 GALAXI program.